Loading...
Loading...
RFL| Name | Value |
|---|---|
| Revenues | 68.0K |
| Cost of Revenue | 18.0K |
| Gross Profit | 50.0K |
| Operating Expense | 2,679.0K |
| Operating I/L | -2,611.0K |
| Other Income/Expense | 4,074.0K |
| Interest Income | 952.0K |
| Pretax | 1,463.0K |
| Income Tax Expense | 4.0K |
| Net Income/Loss | 1,219.0K |
Rafael Holdings, Inc. operates in the pharmaceuticals and real estate sectors. The company leases commercial office space and a public garage while also focusing on the development and commercialization of therapies targeting metabolic differences between normal and cancer cells. Its lead drug candidate, CPI-613 (devimistat), is undergoing clinical trials for metastatic pancreatic cancer and r/r acute myeloid leukemia. The company generates revenue through leasing real estate assets and potentially through the future commercialization of its pharmaceutical products.
